NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
Rhea-AI Summary
NEXGEL (NASDAQ:NXGL) moved its shareholder update conference call to April 21, 2026 at 4:30 P.M. ET to discuss the Celularity transaction. Investors can join via U.S. toll-free 1-800-267-6316, international 1-203-518-9783, or the company webcast under Events and Presentations.
Positive
- None.
Negative
- None.
News Market Reaction – NXGL
On the day this news was published, NXGL declined 1.47%, reflecting a mild negative market reaction. Argus tracked a trough of -12.0% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $81K from the company's valuation, bringing the market cap to $5.43M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NXGL’s move appears stock-specific. Only one peer, POCI, showed momentum scanner activity, moving down ~6% without news, while other sector peers had mixed, smaller moves.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Call rescheduled update | Negative | -15.3% | Rescheduled shareholder call and financing change for Celularity transaction. |
| Apr 08 | Call rescheduled update | Negative | -2.7% | Rescheduled update; noted no assurance Celularity deal will close. |
| Mar 31 | Earnings call shift | Neutral | -1.3% | Moved 2025 results call to focus more on Celularity transaction details. |
| Mar 25 | Earnings date set | Neutral | -1.0% | Announced schedule for Q4 and full-year 2025 results call. |
| Mar 12 | Acquisition terms | Positive | +16.2% | Announced economic terms to license and acquire Celularity biomaterial portfolio. |
Recent Celularity-related and scheduling updates often coincided with modest to sharp declines, while the original Celularity transaction terms drew a strong positive reaction.
Over the last month, NEXGEL has repeatedly updated investors on its proposed Celularity transaction, frequently rescheduling shareholder and earnings-related calls on March 31, April 8, April 15, and April 23. These logistics and uncertainty-focused updates tended to precede modest share price declines. By contrast, the March 12 announcement outlining concrete acquisition terms, including expected revenue impact and profitability, coincided with a notable positive price reaction, highlighting investor focus on transaction economics rather than call timing.
Market Pulse Summary
This announcement advances the shareholder update call on the Celularity transaction to April 21, 2026 at 4:30 P.M. ET, emphasizing management’s intent to address investor questions sooner. Prior months featured multiple reschedulings and one detailed transaction-terms release that coincided with a 16.21% gain. Investors following this story may focus on the upcoming call’s specific disclosures around financing, closing conditions, and how any acquired assets could impact revenue and profitability.
Key Terms
over-the-counter (otc) medical
hydrogel medical
AI-generated analysis. Not financial advice.
LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET.
Shareholder Update Call Details:
Date: April 21, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
